Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 35 years to 85 years old (inclusive) who are ambulatory but suffering from moderate to moderately severe pain from osteoarthritis in the index knee as evidenced by a rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale at screening.~2. Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II, III, IV). Confirmatory x-ray must be taken at Screening and assessed using Kellgren Lawrence grading system.~3. Moderate to moderately-severe OA pain in the index knee even with dosing of nonsteroidal anti-inflammatory drug (NSAID) in the 4 weeks prior to screening.~4. No analgesia (including acetaminophen \[paracetamol\]) taken 12 hours prior to an efficacy measure; and,~5. Able to provide written informed consent to participate in the study.~6. Willing and able to comply with all study requirements and instructions of the site study staff.~Exclusion Criteria:~1. Previous participation in an Ampion™ study.~2. Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the principal investigator.~3. Isolated patella femoral syndrome, also known as chondromalacia.~4. Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g., cancer, congenital defects, spine OA).~5. Major injury to the index knee within the 12 months prior to screening.~6. Severe hip OA ipsilateral to the index knee.~7. Presence of tense effusions.~8. Any pain that could interfere with the assessment of index knee pain (e.g., pain in any other part of the lower extremities, pain radiating to the knee).~9. Initiation or change in any pharmacological or non-pharmacological treatment for OA during the 4 weeks prior to randomization or likely to be changed during the duration of the study.~10. Use of the following medications anticipated to be required during the study:~    * Intra-articular pain medications in the study knee~   * Analgesics containing opioids. (NSAIDs may be continued at levels preceding the study and acetaminophen is available as a rescue medication during the study from the provided supply.)~   * Topical treatment on osteoarthritis index knee needed during the study~   * Use of significant anticoagulant therapy, oral or injectable, during the study (aspirin and clopidogrel are allowed)~   * Systemic treatments that may interfere with safety or efficacy assessments during the study such as immunosuppressants~11. Use of corticosteroids \>10 mg prednisolone equivalent per day (if ≤10 mg prednisolone, the dose must be stable).~12. Use of human albumin treatment in the 3 months before randomization.~13. A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion).~14. A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate).~15. Principal Investigator considers the patient unfit for the study based on medical review and screening.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- AMPION™ 4 mL dose (Type: EXPERIMENTAL): 4 mL injection of Ampion
- Placebo 4 mL dose (Type: PLACEBO_COMPARATOR): 4 mL injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).